ELI LILLY AND COMPANY Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments
ELI LILLY AND COMPANY (LLY) had Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments of $878.00 million as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Notes
us-gaap:FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnfundedCommittments · last filed 2025-10-30
- 2025-09-30: Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments $878.00M.
- 2025-06-30: Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments $835.00M.
- 2025-03-31: Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments $868.00M.
- 2024-12-31: Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments $899.00M.
| Period end | Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unfunded Commitments |
|---|---|
| 2025-09-30 | $878.00M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $835.00M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $868.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $899.00M 10-K · filed 2025-02-19 |
| 2024-09-30 | $925.00M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $900.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $880.00M 10-Q · filed 2024-04-30 |
| 2023-12-31 | $930.00M 10-K · filed 2024-02-21 |
| 2023-09-30 | $915.00M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $925.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $950.00M 10-Q · filed 2023-04-27 |
| 2022-12-31 | $957.00M 10-K · filed 2023-02-22 |
| 2022-09-30 | $854.00M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $980.00M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $843.00M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $828.00M 10-K · filed 2022-02-23 |
| 2021-09-30 | $781.00M 10-Q · filed 2021-10-27 |
| 2021-06-30 | $758.00M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $736.00M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $687.00M 10-K · filed 2021-02-17 |
| 2020-09-30 | $615.00M 10-Q · filed 2020-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |